CAC
NRXPW

Cowen and Company’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Cowen and Company’s Portfolio NRXPW Stock Details NRXPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-58,686
Closed -$4K – 453
2020
Q1 		$4K Buy
58,686
+100
+0.2% +$12 ﹤0.01% 376
2019
Q4 		$10K Hold
58,586
– – ﹤0.01% 389
2019
Q3 		$10K Buy
+58,586
New +$11.4K ﹤0.01% 409

Other funds holding NRXPW

BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Cowen and Company's NRXPW Position: Q2 2020 in Review

Cowen and Company sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q2 2020, closing a stake of 58,686 shares — an estimated $4K sold.

Cowen and Company first reported a position in NRXPW in Q3 2019 and held it in 3 quarters. The position peaked at $10K in Q4 2019. 13 funds tracked by Wall St. Rank hold NRXPW as of Q2 2020.

  • Cowen and Company reported no remaining NRX Pharmaceuticals Warrant position as of Q2 2020 after selling out during the quarter.
  • Cowen and Company sold 58,686 NRX Pharmaceuticals Warrant shares in Q2 2020, an estimated $4K.
  • Cowen and Company first reported a position in NRX Pharmaceuticals Warrant in Q3 2019 and held it in 3 quarters.
  • Cowen and Company's NRX Pharmaceuticals Warrant position peaked at $10K in Q4 2019.
  • 13 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q2 2020.

Based on Cowen and Company's 13F filing for Q2 2020, filed 13 Aug 2020.